Approaches of targeting Rho GTPases in cancer drug discovery
about
sameAs
Structural Mechanisms and Drug Discovery Prospects of Rho GTPasesLysophosphatidylinositol Signalling and Metabolic DiseasesNovel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPasesClinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer.DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.Molecular perturbation strategies to examine spatiotemporal features of Rho GEF and Rho GTPase activity in living cells.Rho GTPases: Anti- or pro-neoplastic targets?The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer.Whole-Genome Sequencing of Salivary Gland Adenoid Cystic CarcinomaIntegrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.Rho GTPases as therapeutic targets in cancer (Review).The R-enantiomer of ketorolac delays mammary tumor development in mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) mice.Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation.A continuous luminescence assay for monitoring kinase activity: signalling the ADP/ATP ratio using a discrete europium complex.Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells.Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma.Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase
P2860
Q26745863-54F7AB6D-DB8B-4087-B395-558D616FC02BQ26771102-44DD416B-1F39-476F-A865-BDD40D7FF9A1Q28550876-0C0BEB9A-25AA-4BF9-A648-BF1B6D0D9243Q33688815-DB7BA8ED-4231-46A0-AC47-C452A0E43BC6Q37675217-32844B96-A8A3-4835-9593-4D66AE5905CCQ38668940-9176C8D3-AE57-40B2-B13C-77D40C65FEC7Q38682208-4B75A724-3516-4850-A3CF-9901DE47799BQ38780866-D7AA74E4-45B8-4041-B554-B7AE166A6C55Q38846822-021B2020-E165-4F53-B8AE-6ED26847FC1DQ38910120-FA438E0F-1E38-403F-B43A-047761323A1BQ41004137-9E10F0BA-1C83-41EA-B974-EC06C13C68ABQ41387997-58AEC636-65CD-4075-AA61-59D65605A93FQ45324338-AF728B04-2B77-4199-9D32-85455B1B802BQ47652910-85C3EE68-0277-4752-A048-32B99F31CE86Q47799871-173A9167-982A-42FD-9C81-9A60A82A2BA3Q50356583-770D6705-D6FE-4475-AD94-BB3427BF97D7Q53320449-B89A00B7-A9E2-46D1-A67B-42401E767230Q59126829-BFAA9A25-1522-4C94-9654-C5E29EDD03EE
P2860
Approaches of targeting Rho GTPases in cancer drug discovery
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Approaches of targeting Rho GTPases in cancer drug discovery
@ast
Approaches of targeting Rho GTPases in cancer drug discovery
@en
Approaches of targeting Rho GTPases in cancer drug discovery
@nl
type
label
Approaches of targeting Rho GTPases in cancer drug discovery
@ast
Approaches of targeting Rho GTPases in cancer drug discovery
@en
Approaches of targeting Rho GTPases in cancer drug discovery
@nl
prefLabel
Approaches of targeting Rho GTPases in cancer drug discovery
@ast
Approaches of targeting Rho GTPases in cancer drug discovery
@en
Approaches of targeting Rho GTPases in cancer drug discovery
@nl
P2860
P3181
P1476
Approaches of targeting Rho GTPases in cancer drug discovery
@en
P2093
P2860
P304
P3181
P356
10.1517/17460441.2015.1058775
P407
P577
2015-01-01T00:00:00Z